EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study

Ryuta Yamamoto, Kazunori Tobino, Hiroya Kawasaki, Hibiki Kiyosue, Hinako Kohri, Mizuki Muranaka, Motoki Yuasa, Shota Sogabe, Kohei Yoshimine

International Journal of Lung Cancer · 2026

DOI: 10.1016/j.ijlcan.2026.100034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Lung Cancer, 2026. Verfasst von Ryuta Yamamoto und 8 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thromboembolic events (TE) are a potentially fatal complication in cancer patients. Vascular endothelial growth factor (VEGF) inhibitors improve survival in non-small cell lung cancer (NSCLC) but may increase thromboembolic risk. Evidence on their safety in patients with prior TE history remains limited.

Methods

In this preliminary retrospective single-center study, NSCLC patients treated at Iizuka Hospital (January 2017–December 2023) were analyzed. Patients receiving VEGF inhibitors (bevacizumab or ramucirumab) were compared with those who did not. TE incidence was estimated using the Kaplan-Meier method; cumulative incidence accounting for competing risks (death) was assessed using the Fine-Gray model.

Results

Of 449 patients, 135 (30.1%) received VEGF inhibitors; TE events occurred in 21 patients (4.7%). TE incidence did not differ significantly between VEGF inhibitor users and non-users (3.7% vs. 5.1%; OR = 0.717; 95% CI: 0.201–2.104; p = 0.631; Fine-Gray SHR = 0.72; 95% CI: 0.26–1.99; p = 0.53). Among VEGF inhibitor recipients with prior TE history (n = 20), only 1 (5.0%) experienced a TE event vs. 4/115 (3.5%) without prior history (OR: 1.16; 95% CI: 0.13–10.47; p = 1.0). Prior TE history was associated with significantly higher overall TE incidence (10.4% vs. 3.5%; OR = 3.19; p = 0.016), driven predominantly by arterial events.

Conclusion

In this preliminary study, VEGF inhibitor use was not statistically associated with increased TE risk in NSCLC patients, including those with prior TE history. However, the limited number of events precludes definitive conclusions regarding safety. These findings provide a foundation for future multicenter prospective studies.

Zitieren

APA

Yamamoto, R., Tobino, K., Kawasaki, H., Kiyosue, H., Kohri, H., Muranaka, M., Yuasa, M., Sogabe, S., & Yoshimine, K. (2026). Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study. International Journal of Lung Cancer. https://doi.org/10.1016/j.ijlcan.2026.100034

Vancouver

Yamamoto R, Tobino K, Kawasaki H, Kiyosue H, Kohri H, Muranaka M, et al. Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study. International Journal of Lung Cancer. 2026. doi:10.1016/j.ijlcan.2026.100034

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Ryuta and Tobino, Kazunori and Kawasaki, Hiroya and Kiyosue, Hibiki and Kohri, Hinako and Muranaka, Mizuki and Yuasa, Motoki and Sogabe, Shota and Yoshimine, Kohei},
  title = {Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study},
  journal = {International Journal of Lung Cancer},
  year = {2026},
  doi = {10.1016/j.ijlcan.2026.100034}
}
Kostenlos starten →